ARS Pharma Lowers 2026 Expense Guidance
ARS Pharma lowers 2026 cash operating expense guidance to $248M and reaffirms path to cash-flow breakeven in 2027
Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
1 result loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
ARS Pharma lowers 2026 cash operating expense guidance to $248M and reaffirms path to cash-flow breakeven in 2027